# Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00706914** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 156 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Once-daily aclidinium/formoterol
- **DRUG:** Twice-daily formoterol fumarate
- **DRUG:** Placebo to formoterol fumarate
- **DRUG:** Once-daily formoterol fumarate

## Key facts

- **NCT ID:** NCT00706914
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06-30
- **Primary completion:** 2008-11-11
- **Final completion:** 2008-11-11
- **Target enrollment:** 156 (ACTUAL)
- **Why stopped:** Actual sample size of 156 was sufficient to estimate the clinical outcomes.
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706914, "Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00706914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*